The prospect of deploying a therapeutic gas — hydrogen — to systematically dismantle a tumor's immune defenses represents a genuinely unconventional frontier in oncology. For health-conscious readers tracking cancer immunotherapy, this review consolidates a fast-moving body of preclinical evidence suggesting that how hydrogen is delivered matters as much as the molecule itself, with metal-based nanocarriers unlocking immune effects that free hydrogen gas cannot reliably achieve.
This systematic review, published in Molecules, maps the immunobiological architecture of nano-metal hydrogen therapy across a range of metallic platforms — calcium, magnesium, iron, copper, and ytterbium among them. Each metal class generates hydrogen through distinct stimuli-responsive mechanisms: pH gradients within the acidic tumor microenvironment, near-infrared light, ultrasound, or localized electrical stimulation. The review's central analytical contribution is characterizing the "metal type–specific activity–immune effect" triad: different metals modulate distinct nodes of the cancer immunity cycle, including dendritic cell-mediated antigen presentation, cytotoxic T-cell priming, and resistance pathways that ordinarily suppress anti-tumor responses. Hydrogen delivery via these nanoplatforms was also associated with induction of immunogenic cell death and sensitization of tumors to conventional radiotherapy and chemotherapy.
Positioning this review within the broader research landscape requires some epistemic caution. Virtually all mechanistic work cited originates from in vitro cell culture and mouse tumor models — human clinical data remain essentially absent. Hydrogen therapy as a clinical modality is itself nascent, with only a small number of early-phase human trials exploring inhaled or dissolved hydrogen in stroke and metabolic disease, not oncology. The nano-metal delivery systems described here add an additional layer of translational complexity: nanoparticle biodistribution, clearance, and off-target immune activation in humans remain uncharacterized for most platforms. This review is best classified as a sophisticated synthesis of preclinical mechanistic science — incremental within the field but valuable as a conceptual roadmap. The signaling pathways identified, particularly those governing immunosuppressive microenvironment reversal, may inform future combination immunotherapy trial design.